Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

NCT03441061 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Inotuzumab Ozogamicin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]